Advertisement

Pituitary

, Volume 22, Issue 2, pp 105–112 | Cite as

Oxytocin alterations and neurocognitive domains in patients with hypopituitarism

  • Yuval EisenbergEmail author
  • Shatha Murad
  • Alessandra Casagrande
  • Mark McArthur
  • Lara R. Dugas
  • Elena Barengolts
  • Brian T. Layden
Article

Abstract

Purpose

Oxytocin is a hypothalamus derived, posterior pituitary stored nonapeptide which has gained recent interest as an important neuropsychiatric and metabolic hormone beyond its classic role in lactation and parturition. Hypopituitarism is a heterogenous disorder of derangement in one or more anterior or posterior pituitary hormones. Diagnosis of deficiency and hormone replacement exists to address all relevant axes except for oxytocin. Our study aims to define derangements in oxytocin in a unique population of patients with hypopituitarism and correlate levels with measures of emotional health and quality of life.

Methods

A cross-sectional, single day study was completed to measure plasma oxytocin levels in a diverse population of patients with hypopituitarism compared to controls. Subjects also completed depression, quality of life and stress-related questionnaires, and emotion recognition tasks.

Results

Thirty-eight subjects completed the study, 18 with hypopituitarism (9 with diabetes insipidus) and 20 controls. After controlling for differences in age, weight and gender, plasma oxytocin levels were highest in subjects with diabetes insipidus compared to control [mean, IQR: 44.3 pg/ml (29.8–78.2) vs. 20.6 (17–31.3), p = 0.032]. Amongst hypopituitary subjects, those with duration of disease greater than 1 year had higher oxytocin levels. No significant differences were observed for psychosocial measures including emotion recognition tasks.

Conclusions

Plasma oxytocin levels were found higher in patients with hypopituitarism compared to controls and highest in those with diabetes insipidus. Longer duration of hypopituitarism was also associated with higher plasma levels of oxytocin. Further study is needed to better define oxytocin deficiency and investigate response to treatment.

Keywords

Oxytocin Hypopituitarism Diabetes Insipidus Neurocognition 

Notes

Acknowledgements

We would also like to acknowledge Dr. Toni Zeigler and her laboratory for assisting in oxytocin measures. Grant support: BTL was supported by the National Institutes of Health under award number, R01DK104927-01A1 and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA merit (Grant No. 1I01BX003382).

Compliance with ethical standards

Disclosure

The authors have nothing to declare.

Supplementary material

11102_2019_936_MOESM1_ESM.xlsx (13 kb)
Supplementary material 1 (XLSX 12 KB)

References

  1. 1.
    Robinson AG, Verbalis JG (2011) Posterior pituitary gland. Williams textbook of endocrinology, 12th edn. Elsevier Inc., PhiladelphiaGoogle Scholar
  2. 2.
    Lawson EA (2017) The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol 13:700–709CrossRefGoogle Scholar
  3. 3.
    Blevins JE, Baskin DG (2015) Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans. Physiol Behav 152:438–449CrossRefGoogle Scholar
  4. 4.
    Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J et al (2013) Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS ONE 8:1–11Google Scholar
  5. 5.
    Lawson E, Marengi D, Desanti RL, Holmes TM, Schoenfeld D, Tolley CJ (2015) Oxytocin reduces caloric intake in men. Obesity 23:950–956CrossRefGoogle Scholar
  6. 6.
    MacDonald K, MacDonald TM (2010) The peptide that binds. Harv Rev Psychiatry 18:1–21CrossRefGoogle Scholar
  7. 7.
    Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673–677CrossRefGoogle Scholar
  8. 8.
    Guastella AJ, Carson DS, Dadds MR, Mitchell PB, Cox RE (2009) Does oxytocin influence the early detection of angry and happy faces? Psychoneuroendocrinology 34:220–225CrossRefGoogle Scholar
  9. 9.
    Cochran DMC, Fallon D, Hill M, Frazier J (2013) The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. Harv Rev Psychiatry 21:219–247CrossRefGoogle Scholar
  10. 10.
    Romano A, Tempesta B, Di Bonaventura MVM, Gaetani S (2016) From autism to eating disorders and more: the role of oxytocin in neuropsychiatric disorders. Front Neurosci 9:1–19CrossRefGoogle Scholar
  11. 11.
    Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M et al (2013) Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 27:57–65CrossRefGoogle Scholar
  12. 12.
    Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG et al (2015) Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophr Res 172:165–168CrossRefGoogle Scholar
  13. 13.
    Mo D, Blum WF, Rosilio M, Webb SM, Qi R, Strasburger CJ (2014) Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab 99:4581–4588CrossRefGoogle Scholar
  14. 14.
    Crespo I, Santos A, Webb SM (2015) Quality of life in patients with hypopituitarism. Curr Opin Endocrinol Diabetes Obes 22:306–312CrossRefGoogle Scholar
  15. 15.
    Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL et al (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs. untreated patients. J Clin Endocrinol Metab 98:980–988CrossRefGoogle Scholar
  16. 16.
    Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, Marín F et al (2003) Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, Questions on Life Satisfaction Hypopituitarism Module. J Clin Endocrinol Metab 88:4158–4167CrossRefGoogle Scholar
  17. 17.
    Daubenbüchel AMM, Hoffmann A, Eveslage M, Özyurt J, Lohle K, Reichel J et al (2016) Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine 54:524–531CrossRefGoogle Scholar
  18. 18.
    Hoffmann A, Özyurt J, Lohle K, Reichel J, Thiel CM, Müller HL (2017) First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine 56:175–185CrossRefGoogle Scholar
  19. 19.
    Daughters K, Manstead ASR, Rees DA (2017) Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. Endocrine 57:166–174CrossRefGoogle Scholar
  20. 20.
    Gebert D, Auer MK, Stieg MR, Freitag MT, Lahne M, Fuss J et al (2018) De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function. Psychoneuroendocrinology 88:61–69CrossRefGoogle Scholar
  21. 21.
    Gur RC, Sara R, Hagendoorn M, Marom O, Hughett P, Macy L et al (2002) A method for obtaining 3-dimensional facial expressions and its standardization for use in neurocognitive studies. J Neurosci Methods 115:137–143CrossRefGoogle Scholar
  22. 22.
    Kanade T, Cohn J, Tian Y (2000) Comprehensive database for facial expression analysis. In: Proceedings of the international conference on automatic face and gesture recognition, pp 46–53Google Scholar
  23. 23.
    Porges SW, Cohn JF, Bal E, Lamb D, Lewis GF (2016) The dynamic affect recognition evaluation software v2. Brain-Body Center for Psychophysiology and BioengineeringGoogle Scholar
  24. 24.
    Eaton W, Muntaner C, Smith C, Tien A, Ybarra M (2004) Center for Epidemiologic Studies Depression Scale: review and revision (CESD and CESD-R). In: Maruish M (ed) The use of psychological testing for treatment planning and outcomes assessment, 3rd edn. Lawrence Erlbaum, Mahwah, pp 363–377Google Scholar
  25. 25.
    Cohen S, Kamarck T, Mermelstein R, Health J, Behavior S, Dec N (1983) A global measure of perceived stress a global measure of perceived stress. J Health Soc Behav 24:385–396CrossRefGoogle Scholar
  26. 26.
    Ruggiero KJ, Del Ben K, Scotti JR, Rabalais AE (2003) Psychometric properties of the PTSD checklist—Civilian version. J Trauma Stress 16:495–502CrossRefGoogle Scholar
  27. 27.
    Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRefGoogle Scholar
  28. 28.
    Seltzer LJ, Ziegler TE, Pollak SD (2010) Social vocalizations can release oxytocin in humans. Proc Biol Sci 277:2661–2666CrossRefGoogle Scholar
  29. 29.
    Leng G, Caquineau C, Sabatier N (2005) Regulation of oxytocin secretion. Vitam Horm 71:27–58CrossRefGoogle Scholar
  30. 30.
    Villar MJ, Meister B, Cortés R, Schalling M, Morris M, Hökfelt T (1990) Neuropeptide gene expression in hypothalamic magnocellular neurons of normal and hypophysectomized rats: a combined immunohistochemical and in situ hybridization study. Neuroscience 36:181–199CrossRefGoogle Scholar
  31. 31.
    Kawamoto K, Kawashima S (1987) Regeneration of neurohypophyseal hormone-producing neurons in hypophysectomized immature rats. Brain Res 422:106–117CrossRefGoogle Scholar
  32. 32.
    Wetsel WC, Fernstrom JD (1987) In vivo biosynthesis of arginine vasopressin and oxytocin in hypothalami from intact and hypophysectomized rats. Endocrinology 120:2562–2568CrossRefGoogle Scholar
  33. 33.
    Dogterom J, Van Wiersma T, Greidansu W, Swaab D (1977) Evidence for the release of vasopressin and oxytocin into cerebrospinal fluid: measurements in plasma and CSF of intact and hypophysectomized rats. Neuroendocrinology 24:108–118CrossRefGoogle Scholar
  34. 34.
    Dyball R, Henry J (1975) Relatively greater increase of oxytocin than vasopressin in the supraoptic nucleus of rats after hypophysectomy. J Endocrinol 64:125–131CrossRefGoogle Scholar
  35. 35.
    Sheward W, Fink G (1991) Effects of corticosterone on the secretion of corticotriphin-releasing factor, arginine vasopressin and oxytocin into hypophysial portal blood in long-term hypophysectomized rats. J Endocrinol 129:91–98CrossRefGoogle Scholar
  36. 36.
    Carter CS, Pournajafi-Nazarloo H, Kramer KM, Ziegler TE, White-Traut R, Bello D et al (2007) Oxytocin: behavioral associations and potential as a salivary biomarker. Ann N Y Acad Sci 1098:312–322CrossRefGoogle Scholar
  37. 37.
    Zeigler TE, Scheffler G, Snowdon CT (1995) The relationship of cortisol levels to social environment and reproductive functioning in female cotton-top tamarin, saguinus oedipus. Horm Behav 29:407–424CrossRefGoogle Scholar
  38. 38.
    Martin J, Kagerbauer SM, Gempt J, Podtschaske A, Hapfelmeier A, Schneider G (2018) Oxytocin levels in saliva correlate better than plasma levels with concentrations in the cerebrospinal fluid of patients in neurocritical care. J Neuroendocrinol 30:e1–e19CrossRefGoogle Scholar
  39. 39.
    Leng G, Sabatier N (2016) Measuring oxytocin and vasopressin: bioassays, immunoassays and random numbers. J Neuroendocrinol.  https://doi.org/10.1111/jne.12413 Google Scholar
  40. 40.
    Francis SM, Kirkpatrick MG, de Wit H, Jacob S (2016) Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration. Psychoneuroendocrinology. 74:92–100CrossRefGoogle Scholar
  41. 41.
    Oxytocin ELISA, Kit, Enzo Life Sciences Inc. [Internet]. 2018 [Cited 8 Feb 2018]. http://www.enzolifesciences.com/ADI-901-153A/oxytocin-elisa-kit/
  42. 42.
    Cook N, Miller J, Hart J (2016) Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. J Pediatr Endocrinol Metab 29:995–1000CrossRefGoogle Scholar
  43. 43.
    Hsu EA, Miller JL, Perez FA, Roth CL (2018) Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection. J Clin Endocrinol Metab 103:370–375CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes, and Metabolism, Department of MedicineUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of Public Health SciencesLoyola UniversityMaywoodUSA
  3. 3.Jesse Brown VA Medical CenterChicagoUSA

Personalised recommendations